8,130 reports of this reaction
4.8% of all EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE reports
#6 most reported adverse reaction
MULTIPLE FRACTURES is the #6 most commonly reported adverse reaction for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, manufactured by Gilead Sciences, Inc. There are 8,130 FDA adverse event reports linking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE to MULTIPLE FRACTURES. This represents approximately 4.8% of all 167,978 adverse event reports for this drug.
Patients taking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE who experience multiple fractures should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE FRACTURES is moderately reported among EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE users, representing a notable but not dominant share of adverse events.
In addition to multiple fractures, the following adverse reactions have been reported for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE:
The following drugs have also been linked to multiple fractures in FDA adverse event reports:
MULTIPLE FRACTURES has been reported as an adverse event in 8,130 FDA reports for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE FRACTURES accounts for approximately 4.8% of all adverse event reports for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, making it a notable side effect.
If you experience multiple fractures while taking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.